Currently the benefits of molecular imaging (MI), which uses gamma cameras to image the distribution of radio-labelled tracers within the body, are largely restricted to patients who can be referred to the Nuclear Medicine (NM) Department of a hospital where the big, expensive, heavy, conventional cameras are sited in dedicated rooms.
Seracam is designed to allow molecular imaging to be routinely taken from the NM Department to the patient, wherever they may be - the outpatient clinic, hospital ward, physician's office, the intensive care unit (ICU), and operating room (OR).
Seracam also has the potential to improve the scanning experience for patients who have trouble keeping still or feel claustrophobic in the full-body scanners; a more comfortable patient is less prone to movement during the exam.
An additional unique feature of Seracam is patented co-registration of the gamma and optical images. This technology is anticipated to make images easier to interpret for the untrained eye, which should enhance physician/patient communication and patients having a better understanding of their condition and treatment options.
Seracam has been designed as a platform technology that can be easily modified to increase its clinical utility. For example, preliminary studies have shown that the optical camera can be readily modified to allow imaging of fluorescent markers, a capability that would be of particular value in surgical oncology. Applications outside the medical imaging field are also being investigated. Obvious adjacencies are in the fields of life sciences (small animal imaging) and veterinary medicine. Opportunities in industrial applications also exist, most notably in the nuclear power industry where the availability of a “camera that can see radiation” could enhance safety.